May influence metabolism w/ CYP2C9 inducers (eg, rifampicin) or inhibitors (eg, fluconazole). Increased AUC w/ fluconazole. Potentiation of blood-glucose-lowering effect & hypoglycemia w/ phenylbutazone, azapropazone & oxyfenbutazone; insulin or oral antidiabetics eg, metformin; salicylates & p-aminosalicylic acid; anabolic steroids & male sex hormones; chloramphenicol, certain long-acting sulfonamides, tetracyclines, quinolones & clarithromycin; coumarin anticoagulants; fenfluramine; disopyramide; fibrates; ACE inhibitors; fluoxetine, MAOIs; allopurinol, probenecid, sulfinpyrazone; sympatholytics; cyclophosphamide, trophosphamide & iphosphamides; miconazole, fluconazole; pentoxifylline (high-dose parenteral); tritoqualine. Weakened blood glucose-lowering effect & raised blood glucose levels w/ estrogens & progestogens; saluretics, thiazide diuretics; thyroid stimulating agents, glucocorticoids; phenothiazine derivatives, chlorpromazine; adrenaline & sympathicomimetics; nicotinic acid (high dosages) & nicotinic acid derivatives; laxatives (long-term use); phenytoin, diazoxide; glucagon, barbiturates & rifampicin; acetazolamide. May either potentiate or weaken blood glucose-lowering effect w/ H
2-antagonist, β-blockers, clonidine & reserpine; alcohol. Reduced or absent signs of adrenergic counter regulation to hypoglycemia w/ sympatholytic drugs eg, β-blockers, clonidine, guanethidine & reserpine. May either potentiate or weaken effects of coumarin derivatives.